ERYTHROPOIETIN TREATMENT OF IDIOPATHIC MYELOFIBROSIS

被引：0
|
作者：
SPIRITI, MAA
LATAGLIATA, R
AVVISATI, G
BATTISTEL, V
MONTEFUSCO, E
SPADEA, A
PETTI, MC
机构：
[1] BOHERINGER MANNHEIM ITALIA,CLIN RES,MONZA,ITALY
[2] UNIV ROMA LA SAPIENZA,DEPT HUMAN BIOPATHOL,I-00185 ROME,ITALY
来源：
HAEMATOLOGICA | 1993年 / 78卷 / 06期
关键词：
IDIOPATHIC MYELOFIBROSIS; ERYTHROPOIETIN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Background. In order to determine whether recombinant human erythropoietin (rHuEPO) may play a role in treating anemia in idiopathic myelofibrosis (IMF), a pilot study using high doses of rHuEPO- was conducted on patients with IMF. Methods and results. From September, 1990 to December, 1992, 7 patients (6 males and 1 female, median age 68 years) affected by IMF entered the trial. RHuEPO was administered subcutaneously 5 days a week at a dosage of 160 U/kg daily for three months. Out of 7 patients, 4 obtained a response. These responders received additional maintenance treatment with rHuEPO until relapse. Response duration was 6, 7, 10+, and 16 months, respectively. Treatment was well-tolerated. Conclusions. Our data suggest that rHuEPO may play a role in the treatment of anemia in some IMF patients.
引用
收藏
页码：371 / 373
页数：3
相关论文
共 50 条
  • [1] Recombinant human erythropoietin for the treatment of anemia in idiopathic myelofibrosis
    Falcone, A
    Musto, P
    Bodenizza, C
    Carotenuto, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 336 - 336
  • [2] Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin
    Hasselbalch, HC
    Clausen, NT
    Jensen, BA
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (02) : 92 - 99
  • [3] Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis
    Leonidas, B
    Aristeidis, C
    Vasiliki, A
    Amalia, V
    Konstantinos, BL
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 74 (03) : 273 - 274
  • [4] Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis
    Tsiara, S. N.
    Chaidos, A.
    Bourantas, L. K.
    Kapsali, H. D.
    Bourantas, K. L.
    [J]. ACTA HAEMATOLOGICA, 2007, 117 (03) : 156 - 161
  • [5] Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin.
    Hasselbalch, HC
    [J]. BLOOD, 1999, 94 (10) : 289B - 289B
  • [6] Treatment of idiopathic myelofibrosis
    Matsukawa, Y
    [J]. ANNALS OF HEMATOLOGY, 2000, 79 (11) : 646 - 647
  • [7] Treatment of idiopathic myelofibrosis
    Y. Matsukawa
    [J]. Annals of Hematology, 2000, 79 : 646 - 647
  • [8] Idiopathic myelofibrosis: pathogenesis to treatment
    Reilly, John T.
    [J]. HEMATOLOGICAL ONCOLOGY, 2006, 24 (02) : 56 - 63
  • [9] Thalidomide for the treatment of idiopathic myelofibrosis
    Strupp, C
    Germing, U
    Scherer, A
    Kündgen, A
    Mödder, U
    Gattermann, N
    Haas, R
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (01) : 52 - 57
  • [10] Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis (vol 74, pg 273, 2005)
    Benetatos, L
    Chaidos, A
    Alymara, V
    Vassou, A
    Bourantas, KL
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (02) : 183 - 183
12345